Immunotherapy Expert Dr. Pawel Kalinski Joins Roswell Park Cancer Institute

Accomplished researcher will focus on translational research, dendritic cell program and tumor microenvironment
Thursday, April 27, 2017
Highlights: 
Dr. Kalinski is a distinguished MD/PhD researcher in field of tumor immunology
Research focuses on cell therapies and manipulation of tumor microenvironments
Rustum Family Professor for Molecular Therapeutics and Translational Research
Dr. Pawel Kalinski, Vice Chair and Rustum Family Professor for Molecular Therapeutics and Translational Research at Roswell Park Cancer Institute.

BUFFALO, N.Y. — Pawel Kalinski, MD, PhD, has joined Roswell Park Cancer Institute as Vice Chair for Translational Research within the Department of Medicine and Director of Cancer Vaccine and Dendritic Cell Therapies within the Center for Immunotherapy. Dr. Kalinski, who has distinguished himself with important research on the immune system and its implications for cancer therapy, joins Roswell Park from the Hillman Cancer Center at the University of Pittsburgh, and will hold the additional titles of Rustum Family Endowed Professor for Molecular Therapeutics and Translational Research, Professor of Oncology and Co-Leader of the Tumor Immunology & Immunotherapy Program.

Dr. Kalinski’s research interests focus on the biology of dendritic cells, T cells and tumor microenvironment-associated myeloid cells. His work will contribute to ongoing important research at Roswell Park’s Center for Immunotherapy through the development of dendritic cell vaccines and dendritic cell-induced T cells, two types of personalized immunotherapy that use patients’ own immune cells to eliminate cancer cells.

“Pawel is a highly sought-after researcher whose interests and abilities will both complement and enhance our Center for Immunotherapy and the broader goals of Roswell Park Cancer Institute. He appropriately views all his activities through the lens of how they can best be integrated into a comprehensive program to improve treatment, outcomes and quality of life for cancer patients. We are honored to welcome him as a colleague,” says Roswell Park Deputy Director, Center for Immunotherapy Executive Director and Chair of Gynecologic Oncology Kunle Odunsi, MD, PhD, FRCOG, FACOG.

Dr. Kalinski earned his medical degree at Warsaw Medical Academy in Poland and a doctorate in immunology from the University of Amsterdam in The Netherlands. He first joined the UPMC Department of Surgery in 2000 as a visiting professor and most recently served as a tenured Professor there. He is active in such professional associations as the American Association of Immunologists, Society for Immunotherapy of Cancer, American Association for Cancer Research and American Society of Clinical Investigation.

###

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-866-559-4838) or email askrpci@roswellpark.org. Follow Roswell Park on Facebook and Twitter.

Media Contact: 

Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org